ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Trinity Appoints Scott Evangelista as CEO to Lead Next Chapter

Trinity, a global leader in technology-enabled commercialization solutions for the life sciences industry, today announced Scott Evangelista has been appointed Chief Executive Officer, succeeding Leslie Orne who is stepping down after three years as CEO and over 24 years with the company. Ms. Orne will transition to the role of Senior Advisor and serve as a member of Trinity’s Board of Directors.

Over her distinguished tenure, Ms. Orne helped guide Trinity’s evolution from a consulting firm to a global commercial solutions provider, and played a key role in shaping the culture and developing future leaders.

A well-recognized pharmaceutical industry executive, Mr. Evangelista brings over 30 years of strategic leadership and operational expertise to Trinity, having previously served in consulting, CRO, and biotechnology senior management roles at global companies. Mr. Evangelista has served on Trinity’s Board of Advisors for the past three years, gaining a deep understanding of the organization, its people, and its clients, and playing a key role in helping management shape the vision and strategy of the company.

“Trinity is focused on becoming the leader in technology-enabled services and products that help clients and employees effectively navigate today’s unprecedented pace of change,” said Matt Jennings, Executive Chairman of Trinity and Operating Partner of Kohlberg. “Scott is a proven leader who knows how to drive transformational growth in companies while preserving and leveraging what makes them exceptional: their people, their expertise, and a deep commitment to excellence. Through his leadership on the board of advisors, he’s demonstrated that he is ideally suited to lead Trinity into its next chapter of growth.”

Mr. Evangelista brings proven leadership experience across both dynamic startups and large multinational organizations, consistently driving results and fostering collaborative, high-performing teams. He currently serves on the board of directors of Worldwide Clinical Trials, advising on growth and innovation as an Operating Executive of Kohlberg, and previously held senior executive leadership roles at IQVIA, Ironshore Pharmaceuticals, and Deloitte, as well as founding of Swiftwater Group. With his oversight as CEO, Trinity will be well positioned to further its mission to power the future of life sciences commercialization by delivering client solutions that bring together human and artificial intelligence.

“Trinity has long been recognized for its client-centric approach and expertise in driving commercialization excellence, and I am honored to join the company at this pivotal time in its journey,” added Mr. Evangelista. “I look forward to building on Trinity’s strong foundation by accelerating innovation, investing in data and technology, and advancing value for patients, clients and employees. I cannot think of an organization better suited to help life sciences companies navigate a dynamic and complex market and I am excited for what’s ahead.”

Jennings concluded: “I want to express our deep appreciation to Leslie for more than twenty years of dedicated service and enduring contributions to both Trinity and the life sciences industry. We look forward to continuing to benefit from her experience as she transitions to Senior Advisor.”

About Trinity

Trinity powers the future of life sciences commercialization through the fusion of human and artificial intelligence. By blending deep therapeutic expertise and trusted human ingenuity with a purpose-built technology platform, Trinity accelerates clarity and confidence at every step of the commercialization journey—from pre-launch to scale to loss of exclusivity. For more than 30 years, the world’s leading pharmaceutical, biotech, and medtech companies have relied on Trinity’s foresight, execution, and partnership to deliver confident product launches, decisive market advantage, and measurable patient impact. During that time, Trinity expanded from its first office in Waltham, MA to 1,300 professionals across 14 offices and five continents, setting new industry standards in quality, responsiveness, and client partnership. For more information, visit Trinity at www.trinitylifesciences.com.

Contacts

Recent Quotes

View More
Symbol Price Change (%)
AMZN  238.38
+4.73 (2.02%)
AAPL  260.48
-0.01 (-0.00%)
AMD  245.04
+8.40 (3.55%)
BAC  52.54
-0.17 (-0.32%)
GOOG  315.72
-0.65 (-0.21%)
META  629.86
+1.47 (0.23%)
MSFT  370.87
-2.20 (-0.59%)
NVDA  188.63
+4.72 (2.57%)
ORCL  138.09
+0.23 (0.17%)
TSLA  348.95
+3.33 (0.96%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.